Wednesday, 1 April 2020

Connective Tissue Disease Market Trends, Analysis And Review During 2019 To 2023

Connective tissues are a group of cellular congregations that provide support and structure to the human body. Connective tissue disease is a group of disorders which involves these protein rich tissues. Protein rich tissues play an important role of supporting organs and other parts of the body. Connective tissue disorders involves multiple organs and organ systems such as, skin, joints, muscles, lungs, kidneys, eyes, heart, gastrointestinal tract, and blood vessels. More than 200 disorders affect the connective tissues. According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population. It is also reported that among Asian population, the condition is more prevalent in China, and Japan. In the European region, the disorder is more prevalent in Italy, Hungary, Norway, and Poland.
Developments in the treatment of connective tissue diseases (CTDs) have been improved considerably, and the global connective tissue disease disorder market is slated to grow at a promising CAGR of 11.5% over the forecast period of 2017-2023. The cause of the disease is unknown and there's no cure for connective tissue disease yet, but medications are present to manage the signs and symptoms. CTDs include a large number of disorders which can affect different organs of the body. There is broad variability in disorders among patient suffering from CTDs.
It is estimated that connective tissue disease market is expected to grow at a CAGR 11.5% during the forecast period of 2017-2023.
A significant increase in the research and development efforts to find treatment and cure for CTDs have aided the growth of the market. Various therapy trials are underway which have been able to identify promising novel approaches to treat CTDs and are expected to boost the growth of the market. Rising prevalence of CTDs across the globe, especially in women has propelled the growth of the market. Additionally, support from governments across the world along with funds for R&D from the private industry is also a key driver of the growth of the market. With the increase in awareness and acceptance among the general population about connective tissue diseases, the diagnosed and drug-treated population will increase which will positively impact the market. Rising expenditure on healthcare, high unmet medical needs of the current treatment and growing prevalence of CTDs in Asia and Africa are expected to promote the growth of the market.  However, the growth of the market might be hindered by lack of a knowledgeable workforce, inadequate research and development infrastructure, lack of funds in middle and low-income countries.
Key Players
Some of key the players in the market are
  • Abbott Laboratories
  • Bayer AG
  • Hoffmann-La Roche Ltd
  • Pfizer
  • AutoImmune Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • AstraZeneca
  • Eli Lilly and Company
  • Biogen
  • LUPIN
Segmentation
The connective tissue disease market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, market is segmented into physical examination, X-ray examination, ANA (Antinuclear Antibody Test), and others.
On the basis of treatment, market is classified into non-steroidal anti-inflammatory drugs (NSAIDs), cortisone drugs/steroids, antimalarial drugs, cytotoxic drugs, and others
On the basis of end-user, market is segmented into hospital, diagnostic clinics, and others.
Regional Analysis
The Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), out of the total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.
Europe holds the second position in the connective tissue disease market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe.
Asia Pacific is the fastest growing market connective tissue disease, owing to a huge patient pool, developing healthcare technology, and rising healthcare expenditure in some countries within this region. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.
The Middle East & Africa has the lowest market for connective tissue disease due to lack of technical knowledge and poor medical facilities. 
Posted by at No comments:

Tuesday, 31 March 2020

Cardiovascular Needle Market: 2020 Global Size, Trends, Investments, Share, Leading Players, Merger, Acquisition, Growth Factors, Regional Analysis, And Industry Forecast To 2023

According to the International Diabetes Federation in 2016, it was estimated that 420 million adult population had diabetes, which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040. Furthermore, increasing prevalence of population suffering from cardiovascular diseases, diabetes, and obesity driving the growth of the cardiovascular needles market globally.
The global cardiovascular needles market is growing rapidly owing to its application in various fields such as open heart surgery, cardiac valve procedures, coronary artery bypass graft surgery, heart transplant, and others.
According to the World Health Organization (WHO) in 2015, around 1.6 million deaths were directly caused by diabetes and in 2014, 8.5% of adults aged 18 years and older had diabetes. Thus, rising prevalence of chronic diseases is majorly driving the global cardiovascular market.
According to the World Health Organization (WHO), in 2015, around 17.7 million people died from cardiovascular diseases, which represents 31% of all global deaths. Of these deaths, around 7.4 million were due to coronary heart disease and 6.7 million were due to stroke.
Various factors are adding fuel to the growth of the global cardiovascular needle market, such as unhealthy diet, low physical activities, etc. According to a research, smoking increases the possibility of diabetes; more than 60% of the global population smokes, this has increased the risk of diabetes and contributed to the growth of the market.
Moreover, advancing technology in the medical devices is adding fuel to the growth of the market. Furthermore, increasing government support in the developing countries drive the market growth.
However, increasing use of surgical staples instead of needles and suture can deter the demand for cardiovascular needles.
The global cardiovascular needle market is expected to grow at a CAGR of 7.2% during the forecast period 2017-2023.
Key Players
Some of the key the players in the market are Becton, Dickinson, and Company (US), B. Braun Melsungen AG (Germany), Sheffield Ltd. (UK), CP Medical, Inc. (the US), Ethicon Inc. (US), KLS Martin Group (US), Sklar Surgical Instruments (US), Rumex International Corporation Ltd. (US), Scanlan International Inc. (US), Teleflex Incorporated (US), Medline Industries, Inc. (US), Surgins surgical Ltd. (UK), Surtex Instruments Ltd. (UK), Cardivon Surgical Inc. (China), Symmetry Surgical Inc. (US), Delacroix-Chevalier (France), Wexler Surgical (US), Quality Needles Pvt. Ltd. (India), FSSB surgical needles GmbH (Germany)
Segmentations
The global cardiovascular needle market is segmented on the basis of types, by application, by usage, and by the end user.
On the basis of the type, it is segmented into round bodied needles and cutting needles. Furthermore, round-bodied needles segmented into taper point needles and blunt point needles. Also, cutting needles segmented into conventional cutting needles and reverse cutting needles.  
On the basis of the application, it is segmented into open heart surgery, cardiac valve procedures, coronary artery bypass graft surgery, heart transplant, and others.  
On the basis of the usage, it is segmented into single use and multiple uses.
On the basis of the end user, it is segmented into hospitals, clinics, ambulatory surgical centers, and others.
Regional Analysis
The Americas dominate the global cardiovascular needle market owing to the rising prevalence of diabetes, obesity, and cardiovascular diseases. Furthermore increasing government support for research & development have fuelled the growth of the market in this region. According to the American Heart Association, in 2017, cardiovascular disease listed as the underlying cause of death which is likely to account for nearly 801,000 deaths in the US by the end of this year. It further estimated that about 2,200 Americans die of cardiovascular disease each day.
Europe holds the second position in the global cardiovascular needle market owing to the presence of major players. Although companies within this region are also involved in export to the developing countries which leads the market of Europe.
The Asia Pacific is the fastest growing Cardiovascular Needle market owing to the high presence of a patient with cardiovascular disease. Furthermore, the government of this region is looking forward to better the quality of needles, which increases the demand for cardiovascular needle market in this region.
On the other hand, in the Middle East and Africa hold the least market due to low research and development activities and poor healthcare infrastructure.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Spinal Needles Market 2020 - Industry Growth, Analysis, Size and Share to 2023

Market Scenario
Spinal needles are medical devices generally used in administration of drug or diagnostic purposes. Spinal needles are inserted into the spinal cord or canal for the collecting cerebrospinal fluid (CSF) for diagnostic testing purposes or drug administration for the treatment of any neurological disease, fractures or vertebroplasty. Spinal anaesthesia is done to temporarily numb the area of pain during spine surgery in which the spinal needles play an important role in the drug administration of anaesthesia. The global spinal needle market share is expected to grow at a CAGR of 6.8% during the forecasted period 2017-2023.
Segmentation
Global spinal needle market is segmented on the basis of type, application and end users.  On the basis of type, the market is segmented into atraumatic needle tips, directional spinal needles, pencil-point needles and others. On the basis of size, the market is segmented into 24G, 25G, 27G and other. On the basis of application, the market is segmented into diagnostic and therapeutic. And on the basis of end users, they are segmented into hospitals, clinics and other.
Key Players
The key players in the global spinal needles market include Argon Medical Devices Inc (Netherland),  B. Braun (Germany), BD (USA), Boston Scientific (USA), Cook Medical (USA), Exel International (USA), Halyard Health (USA), Medline Industries (USA), Medtronic (UK), MYCO Medical (USA), Novo Nordisk (Denmark), Sarstedt (UK), Smiths Medical (USA), Stryker Corporation (USA), and Wallach Surgical (USA).
Regional analysis
The regional segmentation of the global spinal needles market segments the market into continent-based regional markets namely The Americas (North America & South America), Asia Pacific, Europe, and the Middle East & Africa (MEA). The biggest regional market is The Americas. North America alone holds the potential to be the largest market due to its strong economies are known as the United States of America (USA) and Canada. Many key market players are based in the USA. In this region, the availability of advanced medical facilities makes North America a bigger market than South America. Factors supporting the market growth in this region include increasing awareness among the people, an increasing number of spinal surgeries, and the increasing prevalence of different neurological disease.
Decent technological advancement, increasing healthcare expenditure, rising prevalence of diseases, and well-developed healthcare sectors are the reasons that have made Europe the second largest regional market after North America. Due to the reasons same as The Americas, Western Europe is a bigger market than Eastern Europe. The significant country-specific markets in this region are France, Italy, Germany, the United Kingdom (UK), and Spain, followed by the rest of Western Europe and then Eastern Europe.
According to the report, Asia Pacific region is likely to witness a faster growth for the market during the forecast period. Factors contributing to the faster growth include the presence of huge patient population suffering from different infectious diseases and steadily rising quality of medical services in countries like India and Japan. Apart from these two countries, the other country-specific markets are Australia, South Korea, and China, followed by the rest of the Asia Pacific region. 
The MEA region shows limited market slow and steady growth. The reasons for the slow market growth in this region are lack of awareness, lack of education, lack of technological development, political instability, poor healthcare facilities, and healthcare not considered a priority by most governments. The primal country-specific markets in this region are Kuwait, Oman, Qatar, United Arab Emirates (UAE), and Saudi Arabia, followed by the rest of the MEA region.
Latest Industry News
  • Abacus Finance Group LLC has provided senior debt financing to support Zavation Medical Products LLC’s acquisition of Tampa, Florida-based Pan Medical US Corp, a maker of medical products used in minimally invasive procedures. 22 OCT 2018
  • Two University of Virginia alumni have built a new spine-finding device that is giving the practice of identifying the correct insertion point for epidurals and other forms of spinal anesthesia, a much-needed upgrade. 14 JUNE 2018

Intended Audience
  • Spinal needles manufacturers
  • Spinal needles suppliers
  • Research and Development (R&D) companies
  • Independent research laboratories
  • Market research and consulting service providers
  • Medical research laboratories
  • Academic medical institutes and universities
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Distraction Osteogenesis Devices Market Size, Share, Global Analysis, Growth Opportunities, Key Driven Factors, Healthcare Industry Highlights Forecast to 2023

Market Scenario:
The cardiopulmonary disease is a general term used to describe a variety of different diseases and conditions related to heart and lungs. Cardio Vascular Disease is a complex disease with a wide variety of risk factors including those that are modifiable, such as physical inactivity, non-modifiable factors such as age, genes, congenital dispositions, and gender. Respiratory disease is a medical term that includes extreme conditions affecting the organs and tissues which make gas exchange possible in higher organisms. Depending upon the type of cardiopulmonary disease present the treatment options vary and may include changes in diet or lifestyle, use of medications issued on prescription or surgery. The most common cardiopulmonary diseases are hypertension, stroke, and coronary heart disease. Untreated, cardiopulmonary diseases can be deadly. Cardiopulmonary diseases are the major cause of death globally.
The substantial growth in the frequency of health conditions related to the lungs and heart is the key factor to boosts the growth of this market. Also, the increase in aged population and the rising frequency in cardiovascular and respiratory diseases is also anticipated to drive the global market over the forecast period. Exposure to nicotine, tobacco products, and others increases the risk of obtaining cardiopulmonary diseases.
Increase in the rise of advanced technological equipment for diagnosing the disease will drive market rate exponentially. However, the huge cost of treatment and the regulatory nature of government on pharmaceutical companies will hamper the Cardiopulmonary Disease Diagnostics and Treatment market.
Key Players
  • Cardinal Health
  • Cosmed Medical
  • GE Healthcare
  • Halma plc
  • Hill-Rom Holdings, Inc.
  • Koninklijke Philips N.V.
  • MGC Diagnostics Corporation
  • NIHON KOHDEN CORPORATION
  • Schiller AG
  • Masimo Corporation
  • Vyaire Medical Inc
Segmentation
The global cardiopulmonary disease diagnostics and treatment market has been segmented on the basis of disease type, type, and end-user.
On the basis of disease type, the market has been classified as cardiovascular and respiratory diseases. The cardiovascular diseases are segmented into coronary artery disease, angina pectoris, myocardial infarction, dysrhythmia, hypertension, and others. The respiratory diseases are segmented into influenza, asthma, bronchitis, emphysema, cystic fibrosis, and others.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics and rehab centers, research institutes and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis market is segmented into an electrocardiogram (ECG), Holter monitoring, echocardiogram, stress test, cardiac catheterization, cardiac computerized tomography (CT) scan, cardiac magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), stress blood pressure monitors, pulse oximeters and spirometry. The treatment market is segmented into medications. The medications segment is further sub-segmented into angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBS), anticoagulants, antiplatelet agents and others.
The European cardiopulmonary disease diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The cardiopulmonary disease diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cardiopulmonary disease diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Cardiopulmonary Disease Diagnostics and Treatment Market 2020 – Innovation and Advancements In Healthcare Technologies by Types On The Global Industry Size, Trends and Outlook 2023

Market Scenario:
The cardiopulmonary disease is a general term used to describe a variety of different diseases and conditions related to heart and lungs. Cardio Vascular Disease is a complex disease with a wide variety of risk factors including those that are modifiable, such as physical inactivity, non-modifiable factors such as age, genes, congenital dispositions, and gender. Respiratory disease is a medical term that includes extreme conditions affecting the organs and tissues which make gas exchange possible in higher organisms. Depending upon the type of cardiopulmonary disease present the treatment options vary and may include changes in diet or lifestyle, use of medications issued on prescription or surgery. The most common cardiopulmonary diseases are hypertension, stroke, and coronary heart disease. Untreated, cardiopulmonary diseases can be deadly. Cardiopulmonary diseases are the major cause of death globally.
The substantial growth in the frequency of health conditions related to the lungs and heart is the key factor to boosts the growth of this market. Also, the increase in aged population and the rising frequency in cardiovascular and respiratory diseases is also anticipated to drive the global market over the forecast period. Exposure to nicotine, tobacco products, and others increases the risk of obtaining cardiopulmonary diseases.
Increase in the rise of advanced technological equipment for diagnosing the disease will drive market rate exponentially. However, the huge cost of treatment and the regulatory nature of government on pharmaceutical companies will hamper the Cardiopulmonary Disease Diagnostics and Treatment market.
Key Players
  • Cardinal Health
  • Cosmed Medical
  • GE Healthcare
  • Halma plc
  • Hill-Rom Holdings, Inc.
  • Koninklijke Philips N.V.
  • MGC Diagnostics Corporation
  • NIHON KOHDEN CORPORATION
  • Schiller AG
  • Masimo Corporation
  • Vyaire Medical Inc
Segmentation
The global cardiopulmonary disease diagnostics and treatment market has been segmented on the basis of disease type, type, and end-user.
On the basis of disease type, the market has been classified as cardiovascular and respiratory diseases. The cardiovascular diseases are segmented into coronary artery disease, angina pectoris, myocardial infarction, dysrhythmia, hypertension, and others. The respiratory diseases are segmented into influenza, asthma, bronchitis, emphysema, cystic fibrosis, and others.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics and rehab centers, research institutes and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis market is segmented into an electrocardiogram (ECG), Holter monitoring, echocardiogram, stress test, cardiac catheterization, cardiac computerized tomography (CT) scan, cardiac magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), stress blood pressure monitors, pulse oximeters and spirometry. The treatment market is segmented into medications. The medications segment is further sub-segmented into angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBS), anticoagulants, antiplatelet agents and others.
The European cardiopulmonary disease diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The cardiopulmonary disease diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cardiopulmonary disease diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Verrucous Carcinoma Market Size, Share, Global Analysis, Growth Opportunities, Key Driven Factors, Healthcare Industry Highlights Forecast to 2023

Global Verrucous Carcinoma Market Research Report, by Diagnosis (Biopsy, Endoscopy, Imaging Tests), Treatment (Radiation Therapy, Chemotherapy), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Diagnostic Centers) – Global Forecast Till 2023
Market Insights
Verrucous Carcinoma typically debuts as an anomalous growth or as alteration in the constancy of an earlier potentially malignant ailment of the oral cavity. Verrucous Carcinoma is a rare, locally aggressive, clinically exophytic, low-grade, slow-growing, well-differentiated squamous cell carcinoma with nominal metastatic potential. It is unusual subtype of malignant ailment which affects oral cavity. Verrucous Carcinoma can affect all mucosal sites of the oral cavity. However, the frequency of malignant transformation of a leukoplakia to an OVC is considerably higher if they are in the gums in comparison to the tongue.
Verrucous Carcinoma is mainly caused by the snuffing of tobacco or chewing of tobacco. It is also referred to as snuff dipper's cancer. Verrucous Carcinoma mostly prevails at oral zones. The condition common in males within the age group 50 to 80 years. The increasing incidences of oral cancer primarily influences the market. Lifestyle factors such as smoking marijuana or tobacco and alcohol consumption mostly drives the Verrucous Carcinoma market. Additionally, growing consumption of alcohol, increasing adoption of sedentary lifestyle, increasing rates of sexually transmitted viruses by human papillomavirus, and family history of cancer prevalence contribute largely towards the development of the market. In 2015, the World Health Organization reported that 1.1 billion people smoked tobacco globally. This is likely to accelerate the market growth over the forecast period.
However, the high cost of surgical procedures, side effects associated with treatments, and expensive chemotherapy treatments are anticipated to limit the market growth to a certain extent.
Market Segmentation
The worldwide Verrucous Carcinoma market has been segmented based on treatment, end-user, and diagnosis.
Based on treatment, the Verrucous Carcinoma market has been segmented into radiation therapy, surgery, targeted drug therapy, and chemotherapy. Surgery has been sub-segmented into Mohs micrographic surgery and surgical excision. Chemotherapy has been sub-segmented into 5-fluorouracil, bleomycin, methotrexate, cisplatin, and others. Based on end-user, the Verrucous Carcinoma market has been segmented into ambulatory surgical centers, hospitals and clinics, research centers, diagnostic centers, and others. Based on diagnosis, the Verrucous Carcinoma market has been segmented into endoscopy, imaging tests, and biopsy. Imaging tests have been sub-segmented into magnetic resonance imaging, positron emission tomography scans, and computerized tomography scans.
Regional Analysis
The Americas represent the largest Verrucous Carcinoma market share in the global market. The market growth is owing to the increasing healthcare expenditure and surging prevalence of Human Papillomavirus (HPV). As recorded by the Genital HPV Infection, Fact Sheet 2017, 79 million American adults were infested with HPV. Europe (Belgium, UK, Netherlands, and France) represents the second largest Verrucous Carcinoma market over the forecast period. Rising prevalence of head and neck cancer drives the Verrucous Carcinoma market in this region. The Cancer Research UK revealed that in 2015, there were12061 new instances of neck and head cancer. These statistics substantially drive the Verrucous Carcinoma market in Europe.
In 2017, Asia-Pacific was estimated to be the fastest growing region for the worldwide Verrucous Carcinoma market. The market has been expected to develop owing to the rising addiction to smoking. According to the World Health Organization, in 2015, 33.7% and 47.6% of people smoked tobacco in Japan and China, respectively. The Middle East and Africa holds the least market share due to lack of availability of trained healthcare professionals and low per capita income in the region. Nevertheless, the growing palliative and oncology care services both at the community and the hospital level are expected to influence the market positively.
Key Players
The global Verrucous Carcinoma market is dominated by key players such as Qilu Pharmaceutical Co., Ltd. (Asia Pacific), Bristol-Myers Squibb Company (US), Eli Lilly and Company. (US), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Europe), Pfizer Inc. (US), Novartis AG (Europe), and others.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Dyspepsia Market Size, Share, Global Analysis, Growth Opportunities, Key Driven Factors, Healthcare Industry Highlights Forecast to 2023

Global Dyspepsia Market Research Report, by Diagnosis ( Blood Tests, Breath Tests, Stool Tests ), Treatment  (Antacids, Antibiotics, H2 Blockers, Proton Pump Inhibitors), End-User  (Hospital, Clinic, Ambulatory Surgical Centre) - Global Forecast Till 2023
Market Scenario
Dyspepsia is a chronic medical condition which causes discomfort in the upper abdomen as a result of indigestion. The stomach and the small intestine, and sometimes the esophagus does not function properly which is the main reason for the discomfort. Gastritis, peptic ulcers, gallstones, stomach cancer, constipation, reduced blood flow in the intestine are other causes for dyspepsia. Overeating, over-consumption of alcohol and smoking, might also cause dyspepsia. The global dyspepsia market is perceived to be a steadily growing market as per the analysis of market Research Future (MRFR).
Surging prevalence of digestive diseases across the globe is one of the prime reasons for the growth of the global dyspepsia market. The Centers for Disease Control and Prevention estimated 14.7 Mn people in the US to be suffering from digestive ulcers in 2016. Also, the American Cancer Society projected 26,240 new cases of stomach cancer to be diagnosed in the year 2018. The rise in the global geriatric population remains a significant growth driver. The aged populace is generally more susceptible to digestive disorders and induces high demand for diagnosis & treatment. Other factors boosting the growth of the market include the growing occurrence of diabetes and thyroid among the global population. Rigorous R&D activities to develop new drugs and therapies are also likely to augur the growth of the market over the forecast period. Unhealthy diet and a sedentary lifestyle can also be considered as a major reason for the growth of the global dyspepsia market. Due to the current busy lifestyle, consumers are more prone to consuming on-the-go food items which are generally unhealthy and cause digestive disorders. Additionally, such a situation is worsened by smoking and alcohol consumption which favors market growth. On the flipside, the growth of the market might be hindered by high costs associated with diagnostic tests and cut-throat competition among market players.
Segmentation
The global dyspepsia market has been segmented based on diagnosis, treatment, and end user.
By diagnosis, the global dyspepsia market has been segmented into blood tests, breath tests, stool tests, endoscopy, X-ray, CT scan, and others.
By treatment, the global dyspepsia market has been segmented into antacids, antibiotics, h2 blockers, proton pump inhibitors (PPIs), prokinetics, psychological therapies, and others. The antacids segment has been further segmented into calcium carbonate, loperamide, simethicone, sodium bicarbonate, and others. The antibiotic segment has been further segmented into amoxicillin, clarithromycin, metronidazole, and others.  The H2 blockers segment has been further segmented into cimetidine, famotidine, nizatidine, ranitidine, and others. The Proton pump inhibitors (PPIs) segment has been further segmented into esomeprazole, lansoprazole, and omeprazole. Prokinetics are categorized into bethanechol and metoclopramide.
By end user, the global dyspepsia market has been segmented into hospitals and clinics, ambulatory surgical centers, pharmacies, diagnostic centers, and others.
Regional Analysis
By region, the global dyspepsia market has been segmented into the Americas, Europe, Asia-Pacific (APAC), and the Middle East and Africa (MEA).
Competitive Landscape
The notable players in the global dyspepsia market are
  • Allergan Plc,
  • Takeda Pharmaceutical Company,
  • Abbott Laboratories,
  • Johnson & Johnson,
  • Eisai Co., Ltd.,
  • Sanofi,
  • Bayer AG,
  • Salix Pharmaceuticals,
  • AstraZeneca,
  • Boehringer Ingelheim GmbH,
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Posts (Atom)